17 Dec 2021

Hammarskiöld advised Devyser Diagnostics AB (publ) in connection with its IPO on Nasdaq First North Premier Growth Market

Hammarskiöld advised Devyser Diagnostics AB (publ) (“Devyser”) in connection with its IPO on Nasdaq First North Premier Growth Market. Carnegie Investment Bank AB (publ) (“Carnegie”) acted as Sole Global Coordinator and Sole Bookrunner in connection with the IPO.

Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold to routine diagnostic laboratories in more than 45 countries. The products are used for complex DNA testing within hereditary diseases, oncology, and transplantation. The products are used to guide targeted cancer therapies, to enable a wide array of genetic tests, as well as in post-transplant follow-up. Devyser’s product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.

Hammarskiöld’s team mainly consisted of:

Malin Albert (Partner)

Carl-Johan Pousette (Partner)

Aksel Ahlqvist (Associate)

Gustav Wahlberg (Associate)